# Shanghai Guotou Pioneer

> Shanghai Guotou Pioneer is a VC fund in Huangpu backing Health Care and Medical. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Huangpu, China
- Total investments: 14
- Last investment: Aug 2026
- Lead investor: 64%
- Last updated: Aug 2026
- Website: https://www.ssci-leadingfund.com/

Shanghai Guotou Pioneer is a VC fund in Huangpu focused on Health Care and Medical. Shanghai Guotou Pioneer provides investment for companies and projects in the biopharmaceuticals, AI, and integrated chip industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 14% |
| Medical | 1 | 7% |
| Biopharma | 1 | 7% |
| Logistics | 1 | 7% |
| Biotechnology | 1 | 7% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 7% |
| Series A | 1 | 7% |
| Series B | 1 | 7% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| NewPro | NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible. |  | Seed | Aug 04, 2026 |  |
| Yanming Biology | Pyrotech pharmaceuticals is a biotechnology company that focuses om development for drugs for the treatment of inflammation and tumors. |  | Series B | Jul 03, 2026 |  |
| Shadowmo Technology | Shadowmo Technology is a metaverse 3D hyper-realistic image generation and interaction platform dedicated to the creation and application of hyper-realistic virtual avatars. |  | Venture - Series Unknown | Jun 23, 2026 |  |
| YolTech Therapeutics | Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $73.8M | Series C | May 29, 2026 |  |
| TARS | Zhihang Zhong is a prominent researcher in the field of artificial intelligence, particularly known for his work on integrating spatial perception and reasoning into AI systems. | $513.1M | Seed | Apr 16, 2026 |  |
| TARS | TARS (Trusted AI and Robotics Solution) is creating humanoid robots. The AI-driven company specializes in embodied intelligence, integrating large-scale model development, hardware R&D, and the mass production of unified software and hardware solutions. | $513.1M | Seed | Apr 16, 2026 |  |
| Open Source China | Open Source China is a software open source technology community. The community has formed several major channel contents such as open source software libraries, code sharing, information, collaborative translation, discussion forums, and blogs. Users can discover, use, and exchange open source technologies through the community. It also providestechnical questions and answers, software information and other services. |  | Series C | Apr 10, 2026 |  |
| Stairway Medical | Stairway Medical is a developer of implantable brain-computer interface technology. | $72.6M | Venture - Series Unknown | Mar 13, 2026 |  |
| North Ocean Photonics | North Ocean Photonics is a Smart Hardware Company. |  | Series C | Dec 31, 2025 |  |
| Stairway Medical | Stairway Medical is a developer of implantable brain-computer interface technology. |  | Series B | Dec 22, 2025 |  |

10 of 14 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 3 deals together
- [Shanghai Guotou Futeng Capital](https://shizune.co/investors/profile/shanghai-guotou-futeng-capital) — VC Fund, 3 deals together
- [TCL Capital](https://shizune.co/investors/profile/tcl-capital) — VC Fund, 3 deals together
- [Cathay Capital](https://shizune.co/investors/profile/cathaycapital) — VC Fund, 2 deals together
- [Linear Capital](https://shizune.co/investors/profile/linear-capital) — VC Fund, 2 deals together
- [Meituan](https://shizune.co/investors/profile/meituan) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Shanghai Guotou Pioneer invest in?

Shanghai Guotou Pioneer invests primarily in Health Care, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Shanghai Guotou Pioneer last invest?

The most recent investment recorded for Shanghai Guotou Pioneer closed in Aug 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co